Glucocorticoids: Fuelling the Fire of Atherosclerosis or Therapeutic Extinguishers?
Open Access
- 16 July 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (14) , 7622
Abstract
Glucocorticoids are steroid hormones with key roles in the regulation of many physiological systems including energy homeostasis and immunity. However, chronic glucocorticoid excess, highlighted in Cushing’s syndrome, is established as being associated with increased cardiovascular disease (CVD) risk. Atherosclerosis is the major cause of CVD, leading to complications including coronary artery disease, myocardial infarction and heart failure. While the associations between glucocorticoid excess and increased prevalence of these complications are well established, the mechanisms underlying the role of glucocorticoids in development of atheroma are unclear. This review aims to better understand the importance of glucocorticoids in atherosclerosis and to dissect their cell-specific effects on key processes (e.g., contractility, remodelling and lesion development). Clinical and pre-clinical studies have shown both athero-protective and pro-atherogenic responses to glucocorticoids, effects dependent upon their multifactorial actions. Evidence indicates regulation of glucocorticoid bioavailability at the vasculature is complex, with local delivery, pre-receptor metabolism, and receptor expression contributing to responses linked to vascular remodelling and inflammation. Further investigations are required to clarify the mechanisms through which endogenous, local glucocorticoid action and systemic glucocorticoid treatment promote/inhibit atherosclerosis. This will provide greater insights into the potential benefit of glucocorticoid targeted approaches in the treatment of cardiovascular disease.Keywords
This publication has 132 references indexed in Scilit:
- Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP MicePLOS ONE, 2013
- Modulation of 11β-Hydroxysteroid Dehydrogenase as a Strategy to Reduce Vascular InflammationCurrent Atherosclerosis Reports, 2013
- 11β-Hydroxysteroid Dehydrogenase Type 1 Gene Knockout Attenuates Atherosclerosis and In Vivo Foam Cell Formation in Hyperlipidemic apoE−/− MicePLOS ONE, 2013
- 11β‐hydroxysteroid dehydrogenase type 1 deficiency in bone marrow‐derived cells reduces atherosclerosisThe FASEB Journal, 2013
- Glucocorticoids and Type 2 Diabetes: From Physiology to PathologyJournal of Nutrition and Metabolism, 2012
- Cortisol Binding Globulin: More Than Just a Carrier?The Journal of Clinical Endocrinology & Metabolism, 2012
- The role of mediastinal adipose tissue 11β-hydroxysteroid d ehydrogenase type 1 and glucocorticoid expression in the development of coronary atherosclerosis in obese patients with ischemic heart diseaseCardiovascular Diabetology, 2012
- The inhibitory effect of dexamethasone on platelet-derived growth factor-induced vascular smooth muscle cell migration through up-regulating PGC-1α expressionExperimental Cell Research, 2011
- Therapeutic manipulation of glucocorticoid metabolism in cardiovascular diseaseBritish Journal of Pharmacology, 2009
- Hyporesponsiveness to Glucocorticoids in Mice Genetically Deficient for the Corticosteroid Binding GlobulinMolecular and Cellular Biology, 2006